Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00434642
Status:
COMPLETED
Last Update Posted:
2017-08-09
First Post:
2007-02-09
Brief Title:
A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary Peritoneal or Fallopian Tube Carcinoma
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase III Multicenter Randomized Blinded Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary Primary Peritoneal or Fallopian Tube Carcinoma
Status:
COMPLETED
Status Verified Date:
2017-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OCEANS
Brief Summary:
This is a placebo-controlled randomized multicenter Phase III study that will evaluate the safety and efficacy of bevacizumab administered in combination with carboplatin with gemcitabine in women with platinum-sensitive recurrent epithelial ovarian primary peritoneal or fallopian tube carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None